ABOUT US

OXON Epidemiology is a full service global scientific/operational service provider specialising in data collection, secondary data and hybrid observational studies, pragmatic trials, synthesis research, and data analysis and modelling for Safety, Market Access/HEOR and Clinical Development.

Our clients and partners include big and small pharmaceutical companies.

With offices in London, Madrid and Kentucky, OXON applies worldclass epidemiological & operational experience, and innovative technologies to help clients worldwide obtain high quality cost-effective real-world data for improving patients' and public

www.OxonEpi.com

ALL MAJOR THERAPY AREAS, PARTICULARLY:

- Neuroscience
- Metabolic / Diabetes / Bone
- Cardiovascular disease
- Oncology / Haematology
- Orphan conditions
- Immunology
- Vaccines / Infectious diseases
- Respiratory disease
- Gastroenterology
- Ophthalmology
- Paediatrics
- Pregnancy





WWW.OXONEPI.COM

YOUR GLOBAL OBSERVATIONAL STUDIES **SERVICE PROVIDER**

LATE PHASE AND REAL-WORLD EVIDENCE RESEARCH





How can we support you?

As your CRO and scientific service provider, OXON Epidemiology will plan and generate the highest quality Real-World data for Safety, Market access and Drug development.

Our experts can help guide you through all available approaches, designs and implementation options for international field, database and hybrid Real World Evidence (RWE) studies, to meet your needs in the most cost-efficient way.

OXON's close links with centres of excellence at the London School of Hygiene & Tropical Medicine and Oxford University, leading pharmacoepidemiologists in the EU and Asia, as well as our outstanding publication record, including seven publications in The Lancet, and our initiatives at the EMA with ENCePP help us ensure the highest quality of our RWE studies.



Study Types

- Prospective/Registry studies
- Retrospective Chart Review studies
- PASS/PAES
- Database studies
- Disease registries
- Hybrid designs (Field & Database studies)
- PASS/PAES
- Setting up/preparing disease registries
- Risk Minimisation
- Systematic Reviews & Meta-analysis
- Data landscaping studies
- HEOR/Patient Reported Outcomes



Types of Evidence



- Epidemiology: incidence, prevalence, patient characteristics, treatment pathways, etc.
- Drug utilisation: treatment patterns
- PASS and effectiveness of risk minimization measures
- Burden of illness: clinical and healthcare resource utilization & costs
- Comparative effectiveness, safety, healthcare resource utilization & costs
- Country-level inputs from studies for health economic models



PRIMARY/FIELD STUDIES

We work seamlessly with our partners to ensure that the specific requirements of real-world evidence are met in the most cost-effective way.



We understand that matching research objectives with the capabilities of local data sources is an essential step in undertaking valid and credible research.


HYBRID STUDIES

We combine elements of different study designs & data sources to maximise balance of validity, reliability, efficiency and costs, and build a bespoke approach tailored to study objectives.



PATIENT REGISTRIES

Patient registries provide a realworld view of clinical practice, patient and safety outcomes, comparative and cost-effectiveness, and serve to create evidence development and decision-making purposes.



PRAGMATIC TRIALS

OXON offers sponsors its expertise in pragmatic trials using data collection and secondary data sources to help bridge the gap between trials and real-world evidence for Safety and Market Access/HEOR.



SYSTEMATIC REVIEWS & META-ANALYSIS

We use a systematic approach to identify existing literature to appraise and synthesise the best available evidence on a defined question and offer statistical approaches to combine the data derived from any systematic review.



PASS & PAES STUDIES

We assist our clients in designing and conducting post-authorisation safety/efficacy studies, always under the ENCePP guide on methodological standards in pharmacoepidemiology and Code of Conduct.



RISK MINIMISATION STUDIES

OXON delivers studies measuring the effectiveness of routine and additional risk minimization measures (RMMs) for products in most therapy areas and global risk minimisation approaches.



MARKET ACCESS/HEOR

Expertise in health economics and patient-reported outcomes within observational studies to help collect the evidence needed to prove the cost-effectiveness & cost-utility of drugs required by stakeholders.